Sign In
Buy ALX
$281.63
-2.52 (-0.89%)
At Close: Jul 17, 2026
ALX Oncology to Host Virtual R&D Day on March 5, 2025
08:00am, Tuesday, 18'th Feb 2025
SOUTH SAN FRANCISCO, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing th
Inflation Isn't Dead Yet
09:00am, Sunday, 16'th Feb 2025
US equity markets flirted with fresh record-highs this week while benchmark interest rates hovered around two-month lows as investors weighed positive earnings news against uncomfortable hot inflation
Alexander's (ALX) Q4 FFO and Revenues Surpass Estimates
11:25am, Monday, 10'th Feb 2025
Alexander's (ALX) came out with quarterly funds from operations (FFO) of $4.06 per share, beating the Zacks Consensus Estimate of $3.71 per share. This compares to FFO of $4.99 per share a year ago.
Alexander's Announces Fourth Quarter Financial Results
09:15am, Monday, 10'th Feb 2025
PARAMUS, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- ALEXANDER'S, INC. (New York Stock Exchange: ALX) filed its Form 10-K for the year ended December 31, 2024 today and reported:
Alexander's Declares Quarterly $4.50 Dividend on Common Shares
01:00pm, Wednesday, 05'th Feb 2025
PARAMUS, N.J., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that its Board of Directors has declared a regular quarterly dividend of $4.50 per share payable on Febru
Alexander's: Bloomberg Lease Secured, Is The Dividend Safe
10:09pm, Saturday, 25'th Jan 2025
Alexander's has dipped materially from its 52-week high following a spike in the US 10-year Treasury yield. The REIT generated fiscal 2024 third-quarter FFO of $2.84 per share, down from its year-ago
SOUTH SAN FRANCISCO, Calif., Jan. 23, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing th
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
04:01pm, Wednesday, 22'nd Jan 2025
SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings, Inc. (“ALX Oncology” or the “Company”), (Nasdaq: ALXO), a clinical-stage biotechnology company advancing
Alexander's Announces Fourth Quarter Earnings Release Date and Vornado Realty Trust Quarterly Conference Call
12:49pm, Wednesday, 22'nd Jan 2025
PARAMUS, N.J., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that it will file its annual report on Form 10-K for the year ended December 31, 2024 with the U.S. Secu
ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI
05:00pm, Tuesday, 21'st Jan 2025
SOUTH SAN FRANCISCO, Calif., Jan. 21, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing th
SOUTH SAN FRANCISCO, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing the
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Vancouver, British Columbia--(Newsfile Corp. - December 2, 2024) - ALX Resources Corp. (TSXV: AL) (FSE
ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer
08:00am, Thursday, 14'th Nov 2024
Dr. Sandler brings more than 30 years of experience as a distinguished leader in oncology and drug development Dr. Sandler brings more than 30 years of experience as a distinguished leader in oncology
Alexander's Is A Good Business That The Market Has Overestimated
06:00am, Tuesday, 12'th Nov 2024
Alexander's, Inc. has underperformed since 2019, with a -1.7% TSR compared to SPY's 113%, due to declining profitability and rich valuations. Despite increasing NOPAT since 2020, the Company's GAAP ne
A Decisive Realignment
09:00am, Sunday, 10'th Nov 2024
U.S. equity markets soared to record highs this week after President-elect Trump scored a surprisingly decisive election victory, including a likely "trifecta" of Republican legislative control in Con
